Sergey Nikolaevich Tsaplin

Sergey Nikolaevich Tsaplin

Auto-generated profile, based on publicly available information

Sergey Nikolaevich Tsaplin

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ISI. V. Schastlivtsev
I. V. Schastlivtsev
KLKirill Lobastov
Kirill Lobastov
STS. N. Tsaplin
S. N. Tsaplin
DMD. S. Mkrtychev
D. S. Mkrtychev
For many years, there has been no model capable of explaining the complex processes of interaction between various bloodclotting factors leading to a stop of bleeding. One of the most successful models able to partially reflect the mechanisms of hemostasis for a long time was the cascade theory. The cascade model perfectly explains the processes occurring during coagulation in vitro, but was completely inadequate in attempts to evaluate the processes occurring in vivo. A significant drawback of the cascade model is the impossibility to trace the interaction of cells carrying the tissue factor, platelets and plasma coagulation factors on their surface, since these conditions cannot be imitated. The cell theory, which has replaced the cascade theory, pays attention not only to the interaction of plasma coagulation factors, but also takes into account the role of platelets as important participants of coagulation processes. It is based on a four-stage reaction cascade that includes the following stages: initiation, amplification, propagation, and termination.The cell theory of hemostasis is able to reflect the complex process of interaction of all the links of hemostasis and answer questions related to the problems in patients with disorders of the coagulation system. The cell theory of hemostasis allows to reflect more precisely the processes of hemostasis in vivo and to interpret correctly the results of tests and pathophysiological mechanisms of disorders of the coagulation system. Global tests (thrombin generation assay, thromboelastography, thrombodynamics) used for hemostasis system evaluation are more complimentary with cell theory of hemostasis.

16 January 2021 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
KLKirill Lobastov
Kirill Lobastov
ISI. V. Schastlivtsev
I. V. Schastlivtsev
OPOlga Porembskaya
Olga Porembskaya
ODO. V. Dzenina
O. V. Dzenina
ABA. B. Bargandzhiya
A. B. Bargandzhiya
ОПО. Я. Порембская
О. Я. Порембская
The coronavirus infection COVID-19 is a highly contagious disease caused by the SARS-CoV-2 virus. Specific prothrombotic changes of the hemostasis system in COVID-19 are associated with increased incidence of venous thromboembolic complications. The article is a literature review on the diagnosis, treatment and prevention of coagulopathy and venous thromboembolic complications associated with COVID-19. 11 studies evaluating the frequency of registration of venous thromboembolic complications and 11 clinical recommendations on correction of coagulopathy published before May 22, 2020 have been studied. The frequency of venous thromboembolic complications was unexpectedly high: 8–13% in the general ward and 9–18% in the intensive care unit against the background of preventive measures. Preventive doses of anticoagulants, low-molecular weight heparins or unfractionated heparin are indicated to all hospitalized patients. Prolonged prophylaxis after discharge from hospital can be recommended for those at high risk of venous thromboembolic complications and low risk of bleeding. An increase in D-dimer may be considered as an indication for instrumental detection of venous thromboembolic complications. If there is a suspicion of venous thromboembolic complications, anticoagulant therapy at therapeutic doses can be started before the diagnosis is confirmed: during inpatient treatment preference should be given to low-molecular heparin or unfractionated heparin, after discharge from hospital it is recommended to transfer to direct oral anticoagulants for a period of at least 3 months. Routine prevention of venous thromboembolic complications in ambulatory patients is not recommended.

7 September 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
OPOlga Porembskaya
Olga Porembskaya
VKV. N. Kravchuk
V. N. Kravchuk
MGMaxim Galchenko
Maxim Galchenko
RDRoman Deev
Roman Deev
MCM. Sh. Chesnokov
M. Sh. Chesnokov
SSS. A. Sayganov
S. A. Sayganov
Aim. We aimed to study the histological and thrombotic changes in lung vessels in patients who died with COVID-19, to access the correlation between anticoagulation therapy (ACT) and thrombotic events (TE), treatment results, clinical and laboratory patients' characteristics.Material and Methods. We retrospectively analyzed treatment results of patients hospitalized with COVID-19 and lung vessel samples of the deceased patients. Dynamic changes and highest levels of D-dimer and fibrinogen were studied in its correlation with the disease severity according to SOFA score, computer tomographic (CT) results, lung, renal and hepatic dysfunction. The association between different doses of ACT and treatment results, laboratory indicators and thrombotic events was accessed. The histological lung vessels examination was performed using Martius Scarlet Blue (MSB)staining.Results. 313 patients were included in the study (61 patients died). The median age of hospitalized patients was 60 years (IQR 51-66 years). The frequency of the intravitallyconfirmed TE was 4,8%. The strong statistical association was revealed between D-dimer level and 3-4 points SOFA score, patients' mortality, oxygen support requirement, CT3-CT4 pneumonia, glomerular filtration rate and TE. There was no mortality in patients with D-dimer normal references, but in cases with three times elevation reached 13%, 48,5% - in cases with 3-6 times elevation and 64,6% - in cases with more than 6 times elevation. The strong statistical association was registered between fibrinogen and SOFA score, CT 3-4 pneumonia, patients' mortality. D-dimer and fibrinogen levels demonstrated weak correlation. There was no statistical correlation between prophylactic, intermediate and therapeutic ACT and D-dimer and fibrinogen levels, CT results, patients' mortality. MSBstaining was used in 36 deceased patients tissue samples. 1394 lung vessels were analyzed. Lung vessels thrombi persisted in samples of all 36 patients (100%). Vessels with the diameter 3,5-30 mm were thrombosed in 7%, with the diameter 0,034-0,84 mm - in 48%, with the diameter 0,85-3,4 mm - in 45%. The frequency of thrombi persisted 06 hours, 6-12 hours, 12-18hours, 18-24 hours and more than 24 hours was12%, 14%, 62%, 5% and 7% respectively.Conclusion. Thrombi of different ages from fresh to organized were observed in one third of lung vessels in all deceased patients. Lung vessels thrombosis plays an important role in pathogenesis and thanatogenesis of COVID-19. The D-dimer level correlates with lung, renal dysfunction, patients' mortality and doesn't show any correlation with ACT and can be accepted as a criterion of lung vessel thrombotic progression.

17 June 2024 in Journal of Venous Disorders
Verified
Journal Article
Closed access
ISI.V. Schastlivtsev
I.V. Schastlivtsev
KLKirill Lobastov
Kirill Lobastov
STS.N. Tsaplin
S.N. Tsaplin
AMA.V. Matveeva
A.V. Matveeva
SZS.V. Zhuravlev
S.V. Zhuravlev
GRG.V. Rodoman
G.V. Rodoman
OBJECTIVE To evaluate the effectiveness and safety of different anticoagulation regimens for deep vein thrombosis in real clinical practice. MATERIAL AND METHODS We retrospectively analyzed the prospectively collected data on 462 patients with deep vein thrombosis. Patients in the main group received rivaroxaban, in the control group — warfarin. RESULTS The main group included 340 patients (179 men and 161 women aged 26-101 years (mean 61.5±15.6 years), the control group — 122 patients (60 men and 62 women aged 20—93 years (mean 62.0±16.8)). Recurrent venous thromboembolism under anticoagulation occurred in 6 (1.3%; 95% CI 0.6—2.8%) cases (1 (0.3%; 95% CI 0.1—1.7%) and 5 (4.1%; 95% CI 1.8—9.2%) cases, respectively, p=0.006). Bleeding occurred in 49 (10.6%; 95% CI 8.1—13.7%) patients (34 (10.0%; 95% CI 7.2—13.6%) and 15 (12.3%; 95% CI, 7.6—19.3%) patients, respectively, p=0.495). There were 2 (1.6%; 95% CI 0.5—5.8%) major bleeding events under warfarin therapy and no similar events in the main group. The Kaplan-Meier freedom from recurrent thrombosis and major bleeding was significantly in the main group. CONCLUSION Rivaroxaban for the treatment of deep vein thrombosis has made anticoagulation not only effective, but also safe regarding the risk of major bleeding.

29 June 2020 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
KLKirill Lobastov
Kirill Lobastov
ISI. V. Schastlivtsev
I. V. Schastlivtsev
OPOlga Porembskaya
Olga Porembskaya
ODO. V. Dzenina
O. V. Dzenina
ABA. B. Bargandzhiya
A. B. Bargandzhiya
ОПО. Я. Порембская
О. Я. Порембская
The coronavirus infection COVID-19 is a highly contagious disease caused by the SARS-CoV-2 virus. Specific prothrombotic changes of the hemostasis system in COVID-19 are associated with increased incidence of venous thromboembolic complications. The article is a literature review on the diagnosis, treatment and prevention of coagulopathy and venous thromboembolic complications associated with COVID-19. 11 studies evaluating the frequency of registration of venous thromboembolic complications and 11 clinical recommendations on correction of coagulopathy published before May 22, 2020 have been studied. The frequency of venous thromboembolic complications was unexpectedly high: 8-13% in the general ward and 9-18% in the intensive care unit against the background of preventive measures. Preventive doses of anticoagulants, low-molecular weight heparins or unfractionated heparin are indicated to all hospitalized patients. Prolonged prophylaxis after discharge from hospital can be recommended for those at high risk of venous thromboembolic complications and low risk of bleeding. An increase in D-dimer may be considered as an indication for instrumental detection of venous thromboembolic complications. If there is a suspicion of venous thromboembolic complications, anticoagulant therapy at therapeutic doses can be started before the diagnosis is confirmed: during inpatient treatment preference should be given to low-molecular heparin or unfractionated heparin, after discharge from hospital it is recommended to transfer to direct oral anticoagulants for a period of at least 3 months. Routine prevention of venous thromboembolic complications in ambulatory patients is not recommended.

13 September 2020 in Hirurg (Surgeon)
Verified
Journal Article
Closed access
OPOlga Porembskaya
Olga Porembskaya
ОPО. V. Pashovkina
О. V. Pashovkina
STS. N. Tsaplin
S. N. Tsaplin
ISI. V. Schastlivtsev
I. V. Schastlivtsev
SZS. V. Zhuravlev
S. V. Zhuravlev
KLKirill Lobastov
Kirill Lobastov
Pulmonary artery thrombosis is one of the crucial mechanisms of severe COVID-19 development. Histological examination reveals widespread microvascular thrombosis in 87 % and large branches pulmonary artery thrombosis in 13 % of deceased patients. Caused by viral and immune cytotoxic effect thrombotic lung vasculopathy appears to be the main trigger of pulmonary artery thrombosis. In this study we examined 7 lungs obtained from patients who died from COVID-19. Thrombotic lung vasculopathy was typical sign of all 7 lungs. Endothelial cell destruction, media fibrinoid necrosis, neutrophil and lymphocytic infiltrates of the arterial wall and perivascular tissues were the basic histological changes in the lung arteries of different diameters. All this fatal changes developed independently of the therapeutic and prophylactic anticoagulation.